Published: | Last reviewed:
Jacob Schroeder at Kiplinger wrote about a Medicare initiative that drops the price of GLP-1 weight-loss drugs to $50 for beneficiaries, and the fine print underneath it. I work with a lot of Medicare-age clients, and he asked me how I am advising them.
The first thing I told him is that I treat the program's start date as fact rather than forecast, because clients are already planning around it. The second is the trap in the Part D out-of-pocket cap. Clients assume hitting the cap means their drug costs are done for the year. The cap covers Part D drugs; a GLP-1 accessed through a different pathway may not count toward it, so the math on "my costs are capped" can be wrong.
The bigger risk is plan switching. Switching Part D plans to chase GLP-1 access can quietly wreck coverage on someone's other five prescriptions. The savings on one drug can be more than erased by higher tiers or gaps on the others.
For a client who qualifies both ways, through a covered diagnosis and through the new program, I generally point them toward the covered-diagnosis route for the long-term stability, even if the near-term cost looks less predictable. A $50 price is only a good deal if the rest of the coverage survives it.
Read the full article at Kiplinger →
Related services: retirement income planning for retirees and pre-retirees · a retirement readiness assessment
About Jeff Judge, CFP®: meet Jeff and the Chesapeake Financial Planners team.
More press coverage:
Disclosures
The information provided is for educational purposes only and should not be construed as investment advice. Investment strategies should be tailored to individual circumstances, risk tolerance, and goals. Past performance doesn't guarantee future results. Consult with qualified financial professionals regarding your specific situation.
© 2026 Chesapeake Financial Planners | Not to be reproduced in whole or in part. All rights reserved.